Premium
Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus –Associated M embranoproliferative Glomerulonephritis
Author(s) -
Schrezenmeier E.,
Wu K.,
Halleck F.,
Liefeldt L.,
Brakemeier S.,
Bachmann F.,
Kron S.,
Budde K.,
Duerr M.
Publication year - 2017
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.14091
Subject(s) - medicine , membranoproliferative glomerulonephritis , daclatasvir , simeprevir , hemodialysis , gastroenterology , hepatitis c , hepatitis c virus , dialysis , nephrology , transplantation , renal function , kidney , ribavirin , glomerulonephritis , immunology , virus
Recurrence of hepatitis C virus ( HCV )–associated membranoproliferative glomerulonephritis ( MPGN ) in the kidney transplant may lead to continuous graft deterioration and the need for further renal replacement therapy. The novel direct‐acting antiviral agents ( DAA s) allow a highly effective and interferon‐free treatment option for chronic HCV ‐infected patients. Data on the therapeutic safety and efficacy in HCV ‐infected renal transplant patients are sparse, especially for patients with severe renal impairment. We report the case of a 63‐year‐old female HCV ‐positive renal transplant patient with biopsy‐proven recurrence of MPGN in the renal graft 3 years after transplant. Because of rapid loss of transplant function and consecutive need for hemodialysis, we initiated a combined anti‐ HCV –directed therapy regimen consisting of daclatasvir and simeprevir over 12 weeks. Viral clearance of HCV was obtained as early as 2 weeks after start of treatment. No adverse therapy‐associated side effects were observed, and immunosuppressive dosing remained unchanged. Importantly, graft function fully recovered and hemodialysis was stopped 2 mo after the end of daclatasvir/simeprevir treatment. We report the first case of successful recovery of dialysis‐dependent renal transplant failure after treatment of recurrent HCV ‐associated MPGN in a kidney transplant recipient by curing the underlying HCV infection with a combination of novel DAA s.